<SEC-DOCUMENT>0001390478-22-000030.txt : 20221114
<SEC-HEADER>0001390478-22-000030.hdr.sgml : 20221114
<ACCEPTANCE-DATETIME>20221114081716
ACCESSION NUMBER:		0001390478-22-000030
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221114
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221114
DATE AS OF CHANGE:		20221114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELLAS Life Sciences Group, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		221380533

	BUSINESS ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		6462005278

	MAIL ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galena Biopharma, Inc.
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sls-20221114.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:2b5bc447-2098-41cf-9400-9c8fd0db00b1,g:6e17cc8b-4c2e-46e7-baba-05d68bb35c95,d:6f5608fb69d54fe1828e6e9d6b72f961--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sls-20221114</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV80L2ZyYWc6NmZiNzBhZGUxMTE2NDM5YWE5MjcxYjNmOWVlMGRiOGUvdGFibGU6MjY2NTFmZjdmOTljNGYxOGI4OGQ5M2Y5NDM1NGE5YWMvdGFibGVyYW5nZToyNjY1MWZmN2Y5OWM0ZjE4Yjg4ZDkzZjk0MzU0YTlhY18xLTEtMS0xLTQ1MTU1_c07242b4-33eb-42a4-bacc-911dbc3c1db2">0001390478</ix:nonNumeric><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV80L2ZyYWc6NmZiNzBhZGUxMTE2NDM5YWE5MjcxYjNmOWVlMGRiOGUvdGFibGU6MjY2NTFmZjdmOTljNGYxOGI4OGQ5M2Y5NDM1NGE5YWMvdGFibGVyYW5nZToyNjY1MWZmN2Y5OWM0ZjE4Yjg4ZDkzZjk0MzU0YTlhY18yLTEtMS0xLTQ1MTU1_3505e2d3-278a-46b8-9193-6eaf9d4b6ae0">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sls-20221114.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-14</xbrli:startDate><xbrli:endDate>2022-11-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6f5608fb69d54fe1828e6e9d6b72f961_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">UNITED STATES <br/>SECURITIES AND EXCHANGE COMMISSION  <br/>WASHINGTON, D.C. 20549 </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODE4_33ccfc42-602b-4e62-a1c1-eba3c8427cc8">8-K</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">CURRENT REPORT<br/>PURSUANT TO SECTION 13 OR 15(d) OF THE <br/>SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yMzQ_c0b4288c-e3f0-4117-b30c-e855ea9e0e3c">November 14, 2022</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODE0_881be8ea-5ead-4b50-9c65-7db23b163866">SELLAS Life Sciences Group, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.527%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8wLTAtMS0xLTQ1MTU1_e4d9100b-f4db-45db-973c-27d0fe32bdc5">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8wLTItMS0xLTQ1MTU1_b64eea8e-2239-4ed1-8172-1f353d76fb01">001-33958</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8wLTQtMS0xLTQ1MTU1_ccbb518e-61fc-4891-96e3-48eab7a80c1f">20-8099512</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8zLTItMS0xLTQ1MTU1L3RleHRyZWdpb246NmY3MDIyMTIzMTllNDIyZmE0YmJiMTM1NTkyYjc0YjFfNQ_3fa9d57d-0152-4d2b-8fd0-79ca6b83443f">7 Times Square</ix:nonNumeric>, <ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8zLTItMS0xLTQ1MTU1L3RleHRyZWdpb246NmY3MDIyMTIzMTllNDIyZmE0YmJiMTM1NTkyYjc0YjFfOQ_575fcd41-f661-4804-af25-f81668533e40">Suite 2503</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8zLTItMS0xLTQ1MTU1L3RleHRyZWdpb246NmY3MDIyMTIzMTllNDIyZmE0YmJiMTM1NTkyYjc0YjFfMTI_3358115c-c66e-458b-a6bd-527fcb53ee53">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8zLTItMS0xLTQ1MTU1L3RleHRyZWdpb246NmY3MDIyMTIzMTllNDIyZmE0YmJiMTM1NTkyYjc0YjFfMTY_f6a7a687-dfe5-42c9-8512-c0e0c43a063f">NY</ix:nonNumeric> <ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8zLTItMS0xLTQ1MTU1L3RleHRyZWdpb246NmY3MDIyMTIzMTllNDIyZmE0YmJiMTM1NTkyYjc0YjFfMTk_c34a23fb-cbfd-43e9-97c2-aa62d93882b7">10036</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices) (Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV82LTAtMS0xLTQ1MTU1L3RleHRyZWdpb246NjhiYTg1YzRmMWNhNDM4M2E3ODllNmFkNDJkZGFkN2RfNTY_5c156cbb-e33d-4eb4-9c60-1401098a2361">(646)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV82LTAtMS0xLTQ1MTU1L3RleHRyZWdpb246NjhiYTg1YzRmMWNhNDM4M2E3ODllNmFkNDJkZGFkN2RfNTk_7c5ff6cd-d340-41ef-a0b5-1d98c70a4a09">200-5278</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODE1_377d80b0-e018-454c-9b15-4e0f3ab52b4b">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR&#160;230.425) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODE3_cb36ddd5-ae19-43ec-a521-d2b3171e42d8">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR&#160;240.14a-12) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODIx_96e4be7c-54f7-44b7-a72b-45ab5c5b0b7c">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR&#160;240.14d-2(b)) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODIz_e57971ab-b93b-4087-b912-c4a5f3550df0">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR&#160;240.13e-4(c)) </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6N2I0MGQ4ZWQ3NzMxNGFjYzgwN2EyMzNhOTFhMDhhZWIvdGFibGVyYW5nZTo3YjQwZDhlZDc3MzE0YWNjODA3YTIzM2E5MWEwOGFlYl8xLTAtMS0xLTQ1MTU1_055051ac-d859-45d5-b138-9fab9b54da88">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6N2I0MGQ4ZWQ3NzMxNGFjYzgwN2EyMzNhOTFhMDhhZWIvdGFibGVyYW5nZTo3YjQwZDhlZDc3MzE0YWNjODA3YTIzM2E5MWEwOGFlYl8xLTEtMS0xLTQ1MTU1_024cac12-f46f-4004-8506-c3ad285c6097">SLS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6N2I0MGQ4ZWQ3NzMxNGFjYzgwN2EyMzNhOTFhMDhhZWIvdGFibGVyYW5nZTo3YjQwZDhlZDc3MzE0YWNjODA3YTIzM2E5MWEwOGFlYl8xLTItMS0xLTQ1MTU1_17e14ca9-72a2-4ac3-b4f9-2efdc7b44d5e">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter). </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODI0_2e89c811-7ee3-4ad6-b3c9-8d74c93f04e7">&#9744;</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#9744; </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 14, 2022, SELLAS Life Sciences Group, Inc. (&#8220;SELLAS&#8221;) issued a press release (the &#8220;Press Release&#8221;) announcing its financial results for the quarter ended September 30, 2022 and providing a corporate update.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form&#160;8-K&#160;shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form&#160;8-K shall not be incorporated by reference into any filing with the SEC made by SELLAS whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01. Other Events.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 14, 2022, SELLAS issued a press release (the &#8220;REGAL Press Release&#8221;) providing an update on its Phase 3 REGAL clinical trial evaluating its lead asset, galinpepimut-S (&#8220;GPS&#8221;), in acute myeloid leukemia ("AML") patients who have achieved complete remission following second-line salvage therapy. Following consultation with members of the Independent Data Monitoring Committee for the REGAL clinical trial and AML key opinion leaders, as well as the recommendations of SELLAS&#8217;s biostatistics experts, SELLAS is implementing changes to the statistical analysis plan and protocol for the REGAL study, as detailed further in the REGAL Press Release. A copy of the REGAL Press Release is attached hereto as Exhibit 99.2 and is incorporated by reference herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sls-202211148xkexhibit991.htm">Press Release dated November 14, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sls-202211148xkexhibit992.htm">Press Release dated November 14, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SELLAS Life Sciences Group, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 14, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Barbara A. Wood</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbara A. Wood</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel and Corporate Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sls-202211148xkexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9b7149c50ec649898ddd1b35f0a70d2e_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:14pt;font-weight:700;line-height:110%">SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results </font></div><div><font><br></font></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:110%">&#8211;  Cash Position of $21.3 Million as of September 30, 2022 &#8211;</font></div><div><font><br></font></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:110%">&#8211;  Hosting Phase 3 REGAL Study Update Webcast Today at 8&#58;30 a.m. ET &#8211; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%">NEW YORK, November 14, 2022 &#8211; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SELLAS Life Sciences Group, Inc. (NASDAQ&#58; SLS) (&#8220;SELLAS&#8217;&#8217; or the &#8220;Company&#8221;), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications,</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">today provided a business update and reported its financial results for the quarter ended September 30, 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;As announced this morning, we look forward to executing on our revised protocol and statistical analysis plan (SAP) for the Phase 3 registrational REGAL study of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) as well as evaluating the next steps for our ovarian cancer program for GPS in combination with PD1 inhibitors following our release last week of the promising final top-line data from our Phase 1&#47;2 study of GPS in combination with pembrolizumab (Keytruda&#174;).  We are pleased with the preclinical in vitro study results received in the third quarter for GFH009 in neuroendocrine prostate cancer (NEPC), other solid tumors and AML which will help guide our planning for a Phase 2 clinical program for GFH009 in 2023. In addition, we presented data at the 2022 SOHO Meeting, which highlighted bioequivalence data for GFH009 formulations, allowing us to explore a range of dosing strategies and prepare for dosage and administration, and are looking forward to two poster presentations at the upcoming 2022 American Society of Hematology (ASH) meeting in December,&#8221; stated Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;These activities in the third quarter and early fourth quarter are laying the groundwork for the continued advancement in 2023 for both of our clinical programs,&#8221; added Dr. Stergiou.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Pipeline Updates&#58;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:110%">GPS&#58; Wilms Tumor-1 (WT1) targeting peptide immunotherapeutic</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%;padding-left:14.15pt">Phase 3 REGAL Study&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> SELLAS is holding a virtual investor event today at 8.30 am ET to discuss refinements to the protocol and SAP for the REGAL study and the participation of 3D Medicines Inc., SELLAS&#8217; licensee for the development and commercialization of GPS in China, Hong Kong, Macau and Taiwan, in the REGAL study. Webcast information for the update call can be found below. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%;padding-left:14.15pt">Phase 1&#47;2 Study with Keytruda&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">On November 10, 2022, SELLAS announced confirmatory top-line data showing survival and clinical benefits based on the final analysis of the Phase 1&#47;2 clinical trial of GPS in combination with pembrolizumab (Keytruda) in patients with WT1+ relapsed or refractory platinum-resistant advanced ovarian cancer.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%;padding-left:14.15pt">First Patient Dosed in 3DMed Phase 1 Clinical Trial in China&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> In October 2022, SELLAS announced that 3D Medicines dosed the first patient in its Phase 1 clinical trial in China of GPS.  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:110%">GFH009&#58; small molecule, highly selective CDK9 inhibitor</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%;padding-left:14.15pt">Preclinical Results</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#58; In August 2022, SELLAS announced results from preclinical in vitro studies in solid tumor cell lines, including NEPC, and AML cell lines demonstrating significant anti-tumor effects and cancer cell growth inhibition in selected cell lines. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%;padding-left:14.15pt">Phase 1 Clinical Trial Protocol Amendment&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> In July 2022, SELLAS announced that a second, once-a-week dose cohort has been added in its ongoing Phase 1 clinical trial in both the United States and China, beginning at the higher dose level of 30 mg.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Corporate Updates&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%;padding-left:14.15pt">New Board Member&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">In August 2022, SELLAS appointed Katherine Bach Kalin to its Board of Directors. Ms. Kalin&#8217;s healthcare industry experience spans pharmaceuticals, diagnostics, medical devices and digital health.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Results for the Third Quarter 2022&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Licensing revenue&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> There was no licensing revenue for the third quarter of 2022 or 2021. There was $1.0 million in licensing revenue for the nine months ended September 30, 2022, which related to approval by Chinese regulatory authorities of an investigational new drug application by 3D Medicines. This compares to $7.6 million for the nine months ended September 30, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R&#38;D Expenses&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Research and development expenses for the third quarter of 2022 were $4.3 million, compared to $4.5 million for the same period in 2021. The decrease was primarily due to the timing of start-up fees and drug supply purchases in the prior year related to the Company&#8217;s ongoing Phase 3 REGAL clinical trial of GPS in AML patients. Research and development expenses were $14.4 million for the first nine months of 2022, compared to $12.3 million for the same period in 2021. The increase was primarily due to an increase in clinical trial expenses related to the REGAL study and personnel related expenses due to increased headcount. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Acquired In-Process Research and Development&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> There was no acquired in-process research and development for the third quarter of 2022. Acquired in-process research and development was $10.0 million for the first nine months of 2022, resulting from the in-licensing of GFH009. There was no acquired in-process research and development during the same periods in 2021. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">G&#38;A Expenses&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> General and administrative expenses for the third quarter of 2022 were $2.9 million, as compared to $2.4 million for the same period in 2021. The increase was primarily due to personnel related expenses due to increased headcount. General and administrative expenses were $9.0 million for the first nine months of 2022, compared to $8.8 million for the same period in 2021. The increase was primarily due to personnel related expenses due to increased headcount, which were partially offset by a decrease in amortization expense associated with the capitalized contract acquisition costs of the 3D Medicines license agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Net loss was $7.0 million for the third quarter of 2022, or a basic and diluted loss per share of $0.34, compared to a net loss of $7.1 million for the same period in 2021, or a basic and diluted loss per share of $0.45. Net loss was $32.2 million for the first nine months of 2022, or a basic and diluted loss per share of $1.70, compared to a net loss of $14.1 million for the same period in 2021, or a basic and diluted loss per share of $0.92.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Position</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; As of September 30, 2022, cash and cash equivalents totaled approximately $21.3 million.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Webcast Information for Phase 3 REGAL Study Update</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">The Company will host a virtual investor event on its Phase 3 REGAL clinical trial of GPS in patients with AML today at 8&#58;30 a.m. ET. The event will be facilitated by SELLAS management, including SELLAS&#8217; President and CEO, Angelos Stergiou, MD, ScD h.c., and Dragan Cicic, MD, Senior Vice President, Clinical Development, who will be joined by leading cancer researcher, M. Yair Levy, M.D., Director of Hematologic Malignancies Research at the Baylor University Medical Center, and member of the REGAL Steering Committee.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">To attend the live video webcast, please register or email KCSA Strategic Communications at SELLAS&#64;kcsa.com. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">For interested individuals unable to join the live event, an archived version of the webcast will also be available on SELLAS&#8217; Investor Relations site&#58; https&#58;&#47;&#47;www.sellaslifesciences.com&#47;investors&#47;. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%">About SELLAS Life Sciences Group, Inc.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">  SELLAS Life Sciences Group, Inc. (NASDAQ&#58; SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS&#8217; lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">For more information on SELLAS, please visit www.sellaslifesciences.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Keytruda</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7.15pt;font-weight:400;line-height:110%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> is a registered trademark of Merck &#38; Co., Inc., Rahway, N.J., USA (known as MSD outside the United States and Canada) and is not a trademark of SELLAS. The manufacturer of this brand is not affiliated with and does not endorse SELLAS or its products.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:110%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:110%">This press release contains forward-looking statements. All statements other than statements of historical facts are &#8220;forward-looking statements,&#8221; including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;intend,&#8221; or &#8220;continue&#8221; and other words or terms of similar meaning. These statements include, without limitation, statements related to the clinical development of GPS and GFH009 for various cancer indications, including the timing of commencement and completion of, and data from, clinical trials therefor, the potential for GPS and GFH009 as drug development candidates for various cancer indications, alone and in combination with other therapeutic agents. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company&#8217;s clinical plans, risks and uncertainties associated with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption &#8220;Risk Factors&#8221; in SELLAS&#8217; Annual Report on Form 10-K filed on March 31, 2022 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS&#8217; forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Investor Contact</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Allison Soss</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">KCSA Strategic Communications</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Email&#58; SELLAS&#64;kcsa.com </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Phone&#58; 212.896.1267</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Media Contacts</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Raquel Cona &#47; Michaela Fawcett</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">KCSA Strategic Communications</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Email&#58; SELLAS&#64;kcsa.com </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Phone&#58; 516.779.2630</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.573%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,600&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of licensing revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,282&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,541&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,422&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,281&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,864&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,436&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,982&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,794&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,146&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,977&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,504&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,275&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,146)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,977)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,504)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,675)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-operating income (expense), net&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(403)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-operating income (expense), net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(426)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,022)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,085)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,180)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,101)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Per share information&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.34)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.45)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.70)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.92)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,562,351&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,874,076&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,932,571&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,344,210&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.766%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,348&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,355&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,157&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,589&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,605&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,044&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deposits and other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,001&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,275&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,127&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,144&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,570&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development payable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,553&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,982&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,404&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,928&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $0.0001 par value&#59; 5,000,000 shares authorized&#59; Series A convertible preferred stock, 17,500 shares designated&#59; no shares issued and outstanding at September 30, 2022 and December 31, 2021</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Common stock, $0.0001 par value&#59; 350,000,000 shares authorized, 20,588,247 and 15,895,637 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,378&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,948&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(170,783)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138,603)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,597&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,347&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,001&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,275&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>sls-202211148xkexhibit992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0cb38574e705402aa9608bb5b24e6705_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8211; Overall Survival Observed in Pooled Patient Data to Date Leads to Changes in Statistical Analysis Plan&#58; Interim Analysis Now at 60 Events and Final Analysis Now at 80 Events &#8211;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8211; 3D Medicines to Participate in REGAL Clinical Trial, Which Will Trigger Significant Milestone Payments to SELLAS &#8211;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">NEW YORK, NY, November 14, 2022 &#8211; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SELLAS Life Sciences Group, Inc. (NASDAQ&#58; SLS) (&#8220;SELLAS&#8217;&#8217; or the &#8220;Company&#8221;), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced important updates relating to its ongoing Phase 3 open-label registrational clinical trial (the REGAL study) for galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients who have achieved complete remission following second-line salvage therapy (CR2 patients).   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The primary endpoint of the REGAL study is overall survival (OS). The trial was originally designed using certain assumptions regarding OS for both the GPS treatment arm and the control arm receiving best available treatment (BAT) which are reflected in the protocol and statistical analysis plan (SAP) for the study. A review of preliminary data to date, which was pooled (i.e., GPS arm plus control arm) and which remains blinded as to treatment arm, suggests that the median OS in the pooled study population is likely considerably longer, by approximately two-fold, than originally anticipated and upon which the SAP was based. Accordingly, the overall duration of the REGAL study is now expected to be longer than initially predicted. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Following consultation with members of the Independent Data Monitoring Committee for the REGAL study and AML key opinion leaders, as well as the recommendations of the Company&#8217;s biostatistics experts, SELLAS is implementing changes to the SAP and protocol for the REGAL study as follows&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">The total targeted enrollment in the study will increase from 116 patients to a range of 125 to no more than 140 patients.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">The targeted number of events (deaths) for the interim analysis will be reduced to 60 from 80 and is currently expected to occur in late 2023 or early 2024.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">The targeted number of events (deaths) for the final analysis will be reduced to 80 from 105 and is currently expected to occur by the end of 2024. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Statistical significance would be achieved by an estimated hazard ratio (HR) for OS of 0.636, corresponding to an OS of 12.6 months versus eight months for GPS versus BAT, respectively. </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company has developed these changes using a conservative application of the O&#8217;Brien-Fleming statistical theory, which is suitable when regulatory approval is expected to be based predominantly on results from a single clinical trial and when mortality is the primary endpoint.  The Company has notified the U.S. Food and Drug Administration of these changes through a filing to the investigational new drug application (IND) for GPS.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Additionally, SELLAS&#8217; development and commercialization partner for the Greater China territory, 3D Medicines (3DMed), has agreed to participate in the REGAL trial through the inclusion of approximately 20 patients from the Greater China territory. Such participation by 3DMed is possible due to the increase in the target patient enrollment in the study and will trigger significant milestone payments, which SELLAS expects to receive in the first half of 2023. If the REGAL study meets its primary endpoint for efficacy and the Chinese regulatory authorities determine that the REGAL data is sufficient for approval in China, GPS could potentially reach the market in Greater China much earlier than had been anticipated by SELLAS and 3DMed when the parties entered into the license agreement providing rights to 3DMed, triggering additional regulatory and commercialization milestones and royalties for SELLAS. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;The review of the pooled blinded dataset from the REGAL study shows that the entire trial population has a longer than originally expected OS duration,&#8221; said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. &#8220;The causative reason for this result remains unknown and could be attributed to many factors, including the potential for, and extent of, increased clinical benefit accorded by the active GPS arm as well as an evolving treatment landscape and potentially better care for the patients receiving BAT. However, without unblinding the study, it is currently impossible to confirm or refute any of the possibilities. Upon examining the pooled blinded dataset, we worked expeditiously with our biostatisticians and other clinical advisors to refine our SAP, taking into account the observed longer OS, which has resulted in a reduction of the number of events needed for the interim and final analyses while maintaining a similar hazard ratio.&#8221;  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;Furthermore, our team has agreed on a path forward with our partner 3DMed to allow for 3DMed to participate in the REGAL trial and to enroll Chinese patients in a Phase 3 study much earlier than anticipated. This has been made possible by the refinements we are making for the REGAL study. Assuming a statistically significant and clinical beneficial outcome of the REGAL study, as well as agreement by the Chinese regulatory authorities that such data is sufficient for approval in China, GPS may become available to patients in China far earlier than originally thought, which would be a positive outcome for patients in need of better AML therapies,&#8221; continued Dr. Stergiou. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Phase 3 REGAL Study Update Virtual Investor Event </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SELLAS will hold a virtual investor event today, November 14, 2022, at 8&#58;30 a.m. ET at which the Company will discuss these updates. The event will be facilitated by SELLAS management, including the Company&#8217;s President and CEO, Angelos Stergiou, MD, ScD h.c., and Dragan Cicic, MD, Senior Vice President, Clinical Development, who will be joined by leading cancer researcher, M. Yair Levy, M.D., Director of Hematologic Malignancies Research at the Baylor University Medical Center and member of the REGAL Steering Committee.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To attend the live video webcast, please register or email SELLAS&#64;kcsa.com. </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About SELLAS Life Sciences Group, Inc.  </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS&#8217; lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For more information on SELLAS, please visit www.sellaslifesciences.com.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements  </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">This press release contains forward-looking statements. All statements other than statements of historical facts are &#8220;forward-looking statements,&#8221; including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;intend,&#8221; or &#8220;continue&#8221; and other words or terms of similar meaning. These statements include, without limitation, statements related to the global clinical development of GPS and the potential for GPS as a drug development candidate. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company&#8217;s clinical plans and business strategy, risks and uncertainties associated with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption &#8220;Risk Factors&#8221; in SELLAS&#8217; Annual Report on Form 10-K filed on March 31, 2022 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS&#8217; forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Investor Contact  </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Allison Soss  </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">KCSA Strategic Communications  </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Email&#58; SELLAS&#64;kcsa.com  </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Phone&#58; 212.896.1267</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Media Contacts</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Raquel Cona &#47; Michaela Fawcett  </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">KCSA Strategic Communications  </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Email&#58; SELLAS&#64;kcsa.com  </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Phone&#58; 212.896.1276</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>sls-20221114.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2b5bc447-2098-41cf-9400-9c8fd0db00b1,g:6e17cc8b-4c2e-46e7-baba-05d68bb35c95-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sls="http://www.sellaslifesciences.com/20221114" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sellaslifesciences.com/20221114">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20221114_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20221114_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sellaslifesciences.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>sls-20221114_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2b5bc447-2098-41cf-9400-9c8fd0db00b1,g:6e17cc8b-4c2e-46e7-baba-05d68bb35c95-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_a05d33fe-8412-4a0a-adc8-f8781f55b4fc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_f1478861-cdc1-4f7b-975c-7a6ba1b60391_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6d181592-bbfc-4824-85fc-6a2cf98898a9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c106bd19-cfe2-4dd1-88fe-444c1944ac70_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fda2ce46-db01-43de-833a-280cdf0bb885_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_97b8a6a8-0799-43fa-8d63-39424105e878_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_3a1f8345-65d2-400e-8dfb-723006aa3f51_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_d344f605-1514-45dc-bfad-053795dadd9a_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a6dadc3a-8e4f-4642-90e6-6a681096ac17_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_97ca78a8-f0f4-44a4-9734-aa93e06414c4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_76d01461-d9f5-405a-ac3d-5a5b49046400_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_56ef92e6-14d7-48db-9541-65137c7738f4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_c647b5ce-3a32-4664-8507-ecca0405fde6_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6ff2e6e2-a562-41bb-8edc-d3a6c82f3286_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b4861d8d-af93-4a6a-9873-1669336252dc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ad40d981-d325-4bff-8e12-0994c4d3a60f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_db1d76c9-4066-4253-adbc-5f38d8d459d5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e30515fb-acec-4796-b78b-6353b4e60e82_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a0f3be7b-036f-4770-93ca-3bc0209d01c0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4f8ab205-b5d3-4912-938f-a339f12fb3e4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a1fb79bd-ee8a-4c02-bb0b-09ffacc8ea60_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_738badea-3de4-482f-8f40-703c43cfe3dd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_4224be46-7ef5-48c7-a2c8-a8cebddd9406_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>sls-20221114_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2b5bc447-2098-41cf-9400-9c8fd0db00b1,g:6e17cc8b-4c2e-46e7-baba-05d68bb35c95-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sellaslifesciences.com/role/Cover" xlink:type="simple" xlink:href="sls-20221114.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sellaslifesciences.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_df4f95df-da5d-40f2-b356-08dd64f462b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_DocumentType_df4f95df-da5d-40f2-b356-08dd64f462b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ec514c86-dd5a-4df0-ba5e-8e5db242c778" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_DocumentPeriodEndDate_ec514c86-dd5a-4df0-ba5e-8e5db242c778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1149e026-07aa-4c4d-80bf-7393fd1c1704" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_EntityRegistrantName_1149e026-07aa-4c4d-80bf-7393fd1c1704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_72870913-87a0-44d2-b099-ee96f8fe4e4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_72870913-87a0-44d2-b099-ee96f8fe4e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_92ed431d-806c-40ef-a2a1-e5cffd8c5f3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_EntityFileNumber_92ed431d-806c-40ef-a2a1-e5cffd8c5f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c63d32cd-0994-4712-add6-48aaa634df56" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_EntityTaxIdentificationNumber_c63d32cd-0994-4712-add6-48aaa634df56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_56d02a42-0ad8-4fb6-8e6c-d44a89b86830" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_EntityAddressAddressLine1_56d02a42-0ad8-4fb6-8e6c-d44a89b86830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_8a3996dc-2b19-4598-a3b7-220cddd6f277" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_EntityAddressAddressLine2_8a3996dc-2b19-4598-a3b7-220cddd6f277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3187df4e-0593-4c9e-9688-848bb24892eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_EntityAddressCityOrTown_3187df4e-0593-4c9e-9688-848bb24892eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_50794c98-953a-4f03-af48-d4d29404044b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_EntityAddressStateOrProvince_50794c98-953a-4f03-af48-d4d29404044b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_153e62e3-a0ec-4b80-9fe3-a3cfc6474730" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_EntityAddressPostalZipCode_153e62e3-a0ec-4b80-9fe3-a3cfc6474730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d0a9511b-dc84-4c2a-901c-60667b4a77d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_CityAreaCode_d0a9511b-dc84-4c2a-901c-60667b4a77d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_29344f5f-bc22-4670-a4d3-53d764bf9413" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_LocalPhoneNumber_29344f5f-bc22-4670-a4d3-53d764bf9413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_2dd8c0c6-dafe-45ff-88de-b51cf7112c73" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_WrittenCommunications_2dd8c0c6-dafe-45ff-88de-b51cf7112c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_ebb45ea1-f48d-4497-905e-5f0e93804e4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_SolicitingMaterial_ebb45ea1-f48d-4497-905e-5f0e93804e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_85810a3c-0a38-4c51-911d-181dfcaef891" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_PreCommencementTenderOffer_85810a3c-0a38-4c51-911d-181dfcaef891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_ba83a5ea-0bfc-44a4-88c7-5c133d0faa80" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_ba83a5ea-0bfc-44a4-88c7-5c133d0faa80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_90cb09ef-645b-4c61-87d7-704fec71e2e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_Security12bTitle_90cb09ef-645b-4c61-87d7-704fec71e2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1a19109c-d1e5-4413-9601-729f9a459cd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_TradingSymbol_1a19109c-d1e5-4413-9601-729f9a459cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ee5fca0c-139b-4080-88a6-114ad28dfa24" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_SecurityExchangeName_ee5fca0c-139b-4080-88a6-114ad28dfa24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ec02d96f-0464-4650-8c23-3ca5a2537aee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_EntityEmergingGrowthCompany_ec02d96f-0464-4650-8c23-3ca5a2537aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_37ab7efa-79d3-423f-80ec-94fbcb07141e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_EntityCentralIndexKey_37ab7efa-79d3-423f-80ec-94fbcb07141e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6017e4a3-cccb-4f37-9086-f28cd90f3a71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3bbe4892-391e-49e9-a972-1b5c8efb98b1" xlink:to="loc_dei_AmendmentFlag_6017e4a3-cccb-4f37-9086-f28cd90f3a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140387863297872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 14,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELLAS Life Sciences Group, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8099512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7 Times Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">200-5278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>sls-20221114_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sls-20221114.xsd" xlink:type="simple"/>
    <context id="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2022-11-14</startDate>
            <endDate>2022-11-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV80L2ZyYWc6NmZiNzBhZGUxMTE2NDM5YWE5MjcxYjNmOWVlMGRiOGUvdGFibGU6MjY2NTFmZjdmOTljNGYxOGI4OGQ5M2Y5NDM1NGE5YWMvdGFibGVyYW5nZToyNjY1MWZmN2Y5OWM0ZjE4Yjg4ZDkzZjk0MzU0YTlhY18xLTEtMS0xLTQ1MTU1_c07242b4-33eb-42a4-bacc-911dbc3c1db2">0001390478</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV80L2ZyYWc6NmZiNzBhZGUxMTE2NDM5YWE5MjcxYjNmOWVlMGRiOGUvdGFibGU6MjY2NTFmZjdmOTljNGYxOGI4OGQ5M2Y5NDM1NGE5YWMvdGFibGVyYW5nZToyNjY1MWZmN2Y5OWM0ZjE4Yjg4ZDkzZjk0MzU0YTlhY18yLTEtMS0xLTQ1MTU1_3505e2d3-278a-46b8-9193-6eaf9d4b6ae0">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODE4_33ccfc42-602b-4e62-a1c1-eba3c8427cc8">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yMzQ_c0b4288c-e3f0-4117-b30c-e855ea9e0e3c">2022-11-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODE0_881be8ea-5ead-4b50-9c65-7db23b163866">SELLAS Life Sciences Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8wLTAtMS0xLTQ1MTU1_e4d9100b-f4db-45db-973c-27d0fe32bdc5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8wLTItMS0xLTQ1MTU1_b64eea8e-2239-4ed1-8172-1f353d76fb01">001-33958</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8wLTQtMS0xLTQ1MTU1_ccbb518e-61fc-4891-96e3-48eab7a80c1f">20-8099512</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8zLTItMS0xLTQ1MTU1L3RleHRyZWdpb246NmY3MDIyMTIzMTllNDIyZmE0YmJiMTM1NTkyYjc0YjFfNQ_3fa9d57d-0152-4d2b-8fd0-79ca6b83443f">7 Times Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8zLTItMS0xLTQ1MTU1L3RleHRyZWdpb246NmY3MDIyMTIzMTllNDIyZmE0YmJiMTM1NTkyYjc0YjFfOQ_575fcd41-f661-4804-af25-f81668533e40">Suite 2503</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8zLTItMS0xLTQ1MTU1L3RleHRyZWdpb246NmY3MDIyMTIzMTllNDIyZmE0YmJiMTM1NTkyYjc0YjFfMTI_3358115c-c66e-458b-a6bd-527fcb53ee53">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8zLTItMS0xLTQ1MTU1L3RleHRyZWdpb246NmY3MDIyMTIzMTllNDIyZmE0YmJiMTM1NTkyYjc0YjFfMTY_f6a7a687-dfe5-42c9-8512-c0e0c43a063f">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV8zLTItMS0xLTQ1MTU1L3RleHRyZWdpb246NmY3MDIyMTIzMTllNDIyZmE0YmJiMTM1NTkyYjc0YjFfMTk_c34a23fb-cbfd-43e9-97c2-aa62d93882b7">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV82LTAtMS0xLTQ1MTU1L3RleHRyZWdpb246NjhiYTg1YzRmMWNhNDM4M2E3ODllNmFkNDJkZGFkN2RfNTY_5c156cbb-e33d-4eb4-9c60-1401098a2361">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6YTdhNWY5NzM1MzNjNGE4MWEzOWI3ZGMzZjc1Zjk4NTUvdGFibGVyYW5nZTphN2E1Zjk3MzUzM2M0YTgxYTM5YjdkYzNmNzVmOTg1NV82LTAtMS0xLTQ1MTU1L3RleHRyZWdpb246NjhiYTg1YzRmMWNhNDM4M2E3ODllNmFkNDJkZGFkN2RfNTk_7c5ff6cd-d340-41ef-a0b5-1d98c70a4a09">200-5278</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODE1_377d80b0-e018-454c-9b15-4e0f3ab52b4b">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODE3_cb36ddd5-ae19-43ec-a521-d2b3171e42d8">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODIx_96e4be7c-54f7-44b7-a72b-45ab5c5b0b7c">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODIz_e57971ab-b93b-4087-b912-c4a5f3550df0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6N2I0MGQ4ZWQ3NzMxNGFjYzgwN2EyMzNhOTFhMDhhZWIvdGFibGVyYW5nZTo3YjQwZDhlZDc3MzE0YWNjODA3YTIzM2E5MWEwOGFlYl8xLTAtMS0xLTQ1MTU1_055051ac-d859-45d5-b138-9fab9b54da88">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6N2I0MGQ4ZWQ3NzMxNGFjYzgwN2EyMzNhOTFhMDhhZWIvdGFibGVyYW5nZTo3YjQwZDhlZDc3MzE0YWNjODA3YTIzM2E5MWEwOGFlYl8xLTEtMS0xLTQ1MTU1_024cac12-f46f-4004-8506-c3ad285c6097">SLS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGFibGU6N2I0MGQ4ZWQ3NzMxNGFjYzgwN2EyMzNhOTFhMDhhZWIvdGFibGVyYW5nZTo3YjQwZDhlZDc3MzE0YWNjODA3YTIzM2E5MWEwOGFlYl8xLTItMS0xLTQ1MTU1_17e14ca9-72a2-4ac3-b4f9-2efdc7b44d5e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmNTYwOGZiNjlkNTRmZTE4MjhlNmU5ZDZiNzJmOTYxL3NlYzo2ZjU2MDhmYjY5ZDU0ZmUxODI4ZTZlOWQ2YjcyZjk2MV8xL2ZyYWc6NjkzOGE3ODcxOTc3NDBmY2FkYzdlMWI1MzY2NTdlMTkvdGV4dHJlZ2lvbjo2OTM4YTc4NzE5Nzc0MGZjYWRjN2UxYjUzNjY1N2UxOV8yODI0_2e89c811-7ee3-4ad6-b3c9-8d74c93f04e7">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M2F*>=D($MIJ7;7J->5I0E8$ M^HO6EC+)0Q-FN9R[VBFE@H76K#$H"91^7Z
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ )T)N5:K$(A8S 0  (@(   \
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M4$L! A0#%     @ )T)N57(9+)CN    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ )T)N59E<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  G0FY5Y2UMG6($   G$0  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ )T)N59^@&_"Q @  X@P
M  T              ( !I0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  G
M0FY5EXJ[',     3 @  "P              @ &!#P  7W)E;',O+G)E;'-0
M2P$"% ,4    "  G0FY5JL0B%C,!   B @  #P              @ %J$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ )T)N520>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ )T)N5660>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="sls-20221114.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="sls-20221114.htm">sls-20221114.htm</File>
    <File>sls-20221114.xsd</File>
    <File>sls-202211148xkexhibit991.htm</File>
    <File>sls-202211148xkexhibit992.htm</File>
    <File>sls-20221114_lab.xml</File>
    <File>sls-20221114_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sls-20221114.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "sls-20221114.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sls-20221114_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sls-20221114_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sls-20221114.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "sls",
   "nsuri": "http://www.sellaslifesciences.com/20221114",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20221114.htm",
      "contextRef": "i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://www.sellaslifesciences.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20221114.htm",
      "contextRef": "i53f965b4fc044ff294c2d4c5cc807608_D20221114-20221114",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001390478-22-000030-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001390478-22-000030-xbrl.zip
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M.#84%XZ)4\RR*["FL+:@LSMAE:Q7XZ97$5FY:7BKW^)W/-VP]E6I+,;P=P;
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MD^>=G7\J>1&;P'_=M!_N_#]02P,$%     @ )T)N5=\J31=N @  B0<  !
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M4C7%PNU)Y4!@Z,.G<KF)USV6A#Z(AF^%N"98++(%2]%Z=-.^.P?EZ*,F(Q$
M# R6N(@^9"$@&QGTN=4'^(!P?>8$Y"$!F14H05[R!.*$\I,8,L>Z=8)F(XA
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MV1 (AP5[!58*G7+^UVA8Y1"!)?&H!G$V+/FSCX;[FEHT$<_=4SZ@8"R56LY
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M< 3[?A@36"FXF<Q3B2!E1R%:\L>UR7GV5&27T Y_]3AR9@=S?5&:P<.XJ\O
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MBIK$R]0DEFJM&V"A*S_:J;9"&!R 09JF^AQ1G:NC-"+[PFG$+17-(Z%M.5:
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MD4(=V:Y'3%>0Q6HRWXM,VY*WK/3JHG_@R?GG9%9B/S@M5?0&/@ZV3B@O=?8
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MR2-U$@;$;9Z1F@:_XO_IBY%H$O?]$":RY0T=F!Y^;J%V$"O#_NM@>G2CCA7
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MU/M4#C5V'[OJ#?WXB)]K6&0%FPTP+)ZZV8 \*S\X-U>K;DI#>X)IU<\J=&]
M5?>%2J5:1LN::2^1;T_,U52J9/H^+9+BX<SDO9S-/IH;[O^E'J;,9!^,M0*4
M&-"$00:8%!1H&E&D@X 3+:;%XZ">JA1\NUCW7W5RH(<3!]^*!HWF:I'=YN(I
MN\UGMI1ELE69W^@D97.UN&&K&PS,LA!8(C]=@O16*+T*IF=POID\N=2%R-GQ
MZ9F-C)E,U+#,RG(@R[>]S\1A[Y_TM3# *]<72KRZRGY.S+V3LNPJ+T!Y4<FJ
MV>)DY^&]R]<X62X.\+QJ,1&9J75N"E"CO*P-6SI49"V?^Y(ZT^V)E^52Y:9^
MM;A@&7_OI#0/?['ZSP01Y4\U(A&E(0)""@2(CCB(HT" B(6<(1Y"'",W,5MZ
M&:F@5Q!?KB^\$JQW>9>Y"MM&;%MQ]Z1K&(&[,]5!Z'N8Z"%VF]6!!;_'L5W1
M[VO<5?B7[/ZC-,$DT<GR]>O3[9RK?!I*1%$0^X!S+0"A/@$T,%<A\X6.*8TI
MB]W$W]#32 . 0>O5X7I+O*X!H(G@MD'@&6@;)A"X,]8A$!Q@HT<P:+(\<$ X
MX.!N4#ATP_-5!&@J$ RY1#$06IGR7DH$*#75/B%$H)@0)B+8MR) (PT(]CSW
M.57]*P+4HR)PHNM75@3[F'J6B@ =I2*PJ67@B@"Y5 2HA_ O<U;.<E\\S'DV
MFVII4KTB(9 <FO(?2_-6CS$#/H5":L@YI4%;L=<LCTW@*W#>$EU[.=?I.BSA
MSB0<6;8M_7<2J=773L*L6QI,C%8'-@5H;] UVWY(9FI5&,81IRQD%, HCHWN
M- -4AAC@F/@$P4#1B+HEV2?C8Y/>*F.4 #N6UQO$M4VBW>@8)G>V8:)#MMQU
MN4>2W# V<&[<=6,W)5K:N(OR2Z[.LOE<&5SETN['Q>)6Y9?EO'C^66LSUC!#
MFF(2@#"0IA*&T"1'J3F(? QAR!C60>NYL4.=C4VT!B\0&X"])6)O"=FK,+>7
M\4&J#\OZ.0D\LLQ[<><D_+:D= H$!XT/%AC:NKD9*%K?XQXX+K)9(I+"% 9_
M,*/%A,VF$A.B0Q@ %" "2" %X)I)  ,<Q8%D4L:L;:C8-3^VX/"$T%M#;!\+
M+.P=5G\_3HZL=Q<ZG.3=['4G05O,#2;A9E<V1;NG5<\IKC-S^3F_S.[2*0N-
M'H5YR:6*:$!"XH,8JA"$+*0(QB$3*.HTP?74Q]@$NSUI4R(U/'HEUHY36QN$
M.DYL=:-IX&FM5@QUG]+:Y:#_A-:&S5\SG;7K5.-DEJ5I5X%_3$66WV1Y-2]^
M49BX<9;=ID7^<)9)95ZT!8NH>='64)O$3!@!<80)8"S&"H8$$4'<Q+ZWOY$*
MOX;YI5>A+D?W"KE70G>- _MY;QL3GHW-8>)#+R([A(M6]/0('?OM#QQ&6CF[
M&U+:W>8>7LJ]RK,OUUFZGGN*0@D1"1&0L0X @0$#3& ) A9P$D-32<#6*V/;
MQL<6."I\7@70>=)NA[C#P: /'4=6O@,33@)O<KF3FG>,#2;=)C<V==K8IF=1
M_R5;%&SV[^2F2CE!J'3LFT(>$1D!0B4'<4 0" .$(Q%%F&K'5&_K9FQ"W2Y<
MEV ]@[935K<RZUC@=^9KX!J_+57=RWPK$_TK_;K97U/L6UUKK/?MK=WE_SU/
MBD*EY<S>;;K:"[.8BI!$/! *8(9]\T8?EOO88 24$ R:/*VE"MLJW]K#V$2_
M NG54;;7NIW&PS+O3<Z1%>[(BY.P]_K>2=-VBX/)>:]#FTK>W]!=Q.7+_[M<
ML2JWA%J;G*U\P(+0:!=Q#JB2 DC,0D%]C7W:6KN;AL<FV6I"J03GF)9K9!U6
M:%<*CBS,EMX["=+F:B<=U@P-)C\;_$W56;_O(+;LI\K?\461,U&T&4";[<<T
M@DI<WG_6R/[[3&/(YFVW052S--PHLCE0&T;6!AT6/96X-7G@ ?G\,BEF:LH)
M#9&D$C =8T!8R$!,(PQ0&,88AW[@R];' +>-CRUX5Z"\3'O(_QO_N[>&Z[#H
MN<W>82'VX>3(6G2EPVW1L\'O;DN>V\:&6_!L<*.VW-G4QEV>ZQ^HN#2W3IDD
M4,84F2+*#P#A6IN:"OD QC$1I*RLH&XKS4W#8Y/EXZ]RE.#:B['&U6$A=F7@
MR")LY[R3]&R>=I)=S=!@DK/!WY2;]7MWJ;TS-F1IY\.,74TE1S(*10P(#$-
M_  #)KD @<;49$<2Q++U#OJ:Y;&)[1&<5Z)KK[8Z78?EUIF$(^NMI?].@K/Z
MVDEQ=4N#2<[JP*;F[ VZEY_O[\6U>2KJDWE24X5A@ +-@7EB I H#@&/* <A
M#C G*H2*^JXEZ&8'8Y/@&J.W!NF5*-VKT!J)[2O1KM0<69B.K'0J1FVN]RI(
M:P8'+TIM[M@*4VN[KHMV7]554KZ&ID4U[AC4F*N( XA#;<0;01!CP0#F OHP
MEA )QW.F]0[&)M[5ZM,32$?Q6DD\+-Z^U!Q9O(ZL=%B*L[O>8Q%NR^# RV]V
M=W87WAK:=17O^[G*KY+TZI]Y=E=<GV7S&Y8^3(FFC/LP #R0&)#8O&/&F&K
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M+_W_3NR_^B]02P$"% ,4    "  G0FY5^N7=X^H6  "6J   $
M    @ $     <VQS+3(P,C(Q,3$T+FAT;5!+ 0(4 Q0    ( "=";E7?*DT7
M;@(  (D'   0              "  1@7  !S;',M,C R,C$Q,30N>'-D4$L!
M A0#%     @ )T)N515IJ0]E'P  #FH! !T              ( !M!D  '-L
M<RTR,#(R,3$Q-#AX:V5X:&EB:70Y.3$N:'1M4$L! A0#%     @ )T)N5<M_
M]U &$@  !4,  !T              ( !5#D  '-L<RTR,#(R,3$Q-#AX:V5X
M:&EB:70Y.3(N:'1M4$L! A0#%     @ )T)N57R&R5B2"@  $6$  !0
M         ( !E4L  '-L<RTR,#(R,3$Q-%]L86(N>&UL4$L! A0#%     @
M)T)N5>QQA+34!@  "3,  !0              ( !658  '-L<RTR,#(R,3$Q
?-%]P<F4N>&UL4$L%!@     &  8 E@$  %]=      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
